Antihistone Antibodies in Systemic Sclerosis | Zendy

Sato Shinichi | Zendy; Ihn Hironobu | Zendy; Kikuchi Kanako | Zendy; Takehara Kazuhiko | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antihistone Antibodies in Systemic Sclerosis

Author(s) -

Sato Shinichi,

Ihn Hironobu,

Kikuchi Kanako,

Takehara Kazuhiko

Publication year - 1994

Publication title -

arthritis & rheumatism

Language(s) - English

Resource type - Journals

eISSN - 1529-0131

pISSN - 0004-3591

DOI - 10.1002/art.1780370313

Subject(s) - serology , medicine , scleroderma (fungus) , autoantibody , antibody , pulmonary fibrosis , immunology , antigen , connective tissue disease , systemic disease , immunopathology , fibrosis , pathology , autoimmune disease , inoculation

Objective . To determine the prevalence and clinical significance of antihistone antibodies (AHA) in systemic sclerosis (SSc). Methods . Serum samples from patients with limited cutaneous SSc (n = 44), diffuse cutaneous SSc (dcSSc; n = 48), and other SSc‐related disorders (n = 22) were examined by enzyme‐linked immunosorbent assay and immunoblotting for AHA. Results . AHA were demonstrated in 29% of the 92 SSc patients and in 44% of those with dcSSc. The presence of AHA correlated with severe pulmonary fibrosis in those with dcSSc. Immunoblotting revealed that the predominant antigen was histone H1. Conclusion . AHA might be a serologic indicator of the severity of pulmonary fibrosis in SSc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research